A New Generation of Precisely Engineered CD74-Targeting ADC

South San Francisco (Press Release) – Sutro Biopharma, Inc. (NASDAQ: STRO), has been granted Orphan Drug Desig­na­tion by the United States Food and Drug Admin­istra­tion (FDA) for STRO-001 for the treat­ment of multiple myeloma. STRO-001 is a poten­tial first-in-class anti­body drug con­ju­gate (ADC) targeting CD74, a protein highly ex­pressed in B-cell malig­nan­cies such as multiple myeloma.

"There is a growing need for new treat­ment options for patients with multiple myeloma," commented Bill Newell, Sutro's Chief Executive Officer. "This Orphan Drug Desig­na­tion is a great step to­wards ad­vanc­ing our uniquely designed STRO-001 that could bring …